enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Update

Key Points

• Short interest in enGene Holdings Inc. decreased by 54.5% as of August 15th, from 10,100 shares to 4,600 shares, indicating reduced bearish sentiment towards the stock.
• Several hedge funds significantly increased their holdings in enGene during the fourth quarter, with Deep Track Capital LP raising its stake by 74.8% to approximately 4.56 million shares.
• The stock opened at $4.87 with a market cap of $248.86 million, while the company reported a Q1 EPS of (0.51), missing estimates.

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 15th, there was short interest totaling 4,600 shares, adecreaseof54.5% from the July 31st total of 10,100 shares. Approximately0.0% of the shares of the company are short sold. Based on an average trading volume of 82,900 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 82,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately0.0% of the shares of the company are short sold.

Hedge Funds Weigh In On enGene

A number of institutional investors and hedge funds have recently made changes to their positions in ENGN. Fcpm Iii Services B.V. boosted its stake in shares of enGene by 11.0% during the 4th quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock worth $64,057,000 after purchasing an additional 954,610 shares during the last quarter. VR Adviser LLC lifted its holdings in enGene by 41.5% in the 4th quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock worth $33,559,000 after buying an additional 1,480,573 shares in the last quarter. Deep Track Capital LP grew its position in shares of enGene by 74.8% during the 4th quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock valued at $30,308,000 after buying an additional 1,949,942 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of enGene by 2.7% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,571,642 shares of the company's stock valued at $7,041,000 after buying an additional 41,874 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of enGene by 84.7% during the fourth quarter. Point72 Asset Management L.P. now owns 1,224,797 shares of the company's stock valued at $8,145,000 after acquiring an additional 561,797 shares during the period. 64.16% of the stock is owned by institutional investors and hedge funds.

enGene Price Performance

Shares of NASDAQ:ENGN traded up $0.18 during midday trading on Friday, hitting $5.18. The company's stock had a trading volume of 125,192 shares, compared to its average volume of 164,669. The business's 50 day simple moving average is $3.92 and its 200 day simple moving average is $4.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.66 and a current ratio of 12.66. The company has a market cap of $264.70 million, a P/E ratio of -3.14 and a beta of -0.39. enGene has a 12-month low of $2.65 and a 12-month high of $11.00.

enGene (NASDAQ:ENGN - Get Free Report) last issued its earnings results on Tuesday, June 10th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.03). On average, analysts forecast that enGene will post -1.56 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.